{"id":"NCT01854632","sponsor":"PATH","briefTitle":"Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Trial of the Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2013-05-15","resultsPosted":"2015-06-03","lastUpdate":"2015-06-03"},"enrollment":1761,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"SIIL Live Attenuated Influenza Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Matched placebo","otherNames":[]}],"arms":[{"label":"SIIL Live Attenuated Influenza Vaccine","type":"EXPERIMENTAL"},{"label":"Matched placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will provide the Senegal Ministry of Health with data on the clinical efficacy of the Live-Attenuated Influenza Vaccine (LAIV). This data will inform future policy considerations for influenza vaccine.","primaryOutcome":{"measure":"Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Regardless of Vaccine Match)","timeFrame":"Through 7 to 8 months post vaccination","effectByArm":[{"arm":"Vaccine","deltaMin":17.9,"sd":null},{"arm":"Placebo","deltaMin":18,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.996"}]},"eligibility":{"minAge":"24 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":1,"countries":["Senegal"]},"refs":{"pmids":["27746224"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":1174},"commonTop":["Non Respiratory AEs","Respiratory AEs"]}}